A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol

Sponsor

AstraZeneca (Industry)

Overall Status

Completed

CT.gov ID

NCT04550234

Collaborator

Parexel (Industry)

Enrollment

Location

Arms

3.1

Actual Duration (Months)

8.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female subjects. This study is intended to assess the relative bioavailability between the fixed dose combination (FDC, i.e. verinurad/allopurinol FDC capsule 12/300 mg) and free combination formulations of verinurad (i.e. verinurad prolonged release Hydroxypropyl methylcellulose [HPMC] capsule 12 mg) and allopurinol (i.e. allopurinol table 300 mg) in fasted and fed conditions. The study will also assess the relative bioavailability between a formulation only containing verinurad (i.e. verinurad prolonged release gelatin capsule 12 mg) and the FDC capsule.

Condition or Disease	Intervention/Treatment	Phase
Chronic Kidney Disease	Drug: Verinurad prolonged release HPMC capsule Drug: Allopurinol Tablet Drug: Verinurad/Allopurinol FDC Capsule Drug: Verinurad prolonged release gelatin Capsule	Phase 1

Detailed Description

The study comprises of:

A Screening Period of maximum 28 days;
Five treatment periods during which subjects will be resident from the morning of Day -2 until at least 72 hours after dosing in Treatment Period 5; discharged on the morning of Day 4 of Treatment Period 5; and
A Follow-up Visit 7 to 14 days after the last dosing.

Each subject will receive 5 single dose treatments of verinurad and allopurinol or verinurad alone and subject will be involved in the study for 52 to 59 days.

Study Design

Study Type:

Interventional

Actual Enrollment :

25 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Randomised, Single Dose, 5-period, 5-treatment, Crossover Study to Assess the Relative Bioavailability of 4 Different Formulations of Verinurad and Allopurinol in Healthy Subjects

Actual Study Start Date :

Apr 13, 2021

Actual Primary Completion Date :

Jul 15, 2021

Actual Study Completion Date :

Jul 15, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment 1 Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fasted state on Day 1.	Drug: Verinurad prolonged release HPMC capsule Randomized subjects will receive oral dose of verinurad HPMC capsule. Drug: Allopurinol Tablet Randomized subjects will receive oral dose of allopurinol tablet.
Experimental: Treatment 2 Subjects will receive verinurad/allopurinol FDC capsule in fasted state on Day 1.	Drug: Verinurad/Allopurinol FDC Capsule Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.
Experimental: Treatment 3 Subjects will receive verinurad/allopurinol FDC capsule in fed state on Day 1.	Drug: Verinurad/Allopurinol FDC Capsule Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.
Experimental: Treatment 4 Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fed state on Day 1.	Drug: Verinurad prolonged release HPMC capsule Randomized subjects will receive oral dose of verinurad HPMC capsule. Drug: Allopurinol Tablet Randomized subjects will receive oral dose of allopurinol tablet.
Experimental: Treatment 5 Subjects will receive verinurad prolonged release gelatin capsule in fasted state on Day 1.	Drug: Verinurad prolonged release gelatin Capsule Randomized subjects will receive oral dose of Verinurad gelatin capsule.

Outcome Measures

Primary Outcome Measures

Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol (VAO) after dosing with verinurad/allopurinol FDC capsule and free combinations of verinurad and allupurinol (V/A) under fasted conditions by AUCinf [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and12 hours [h] post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose;Day 4: 72 h post-dose)]
Area under plasma concentration time curve from time zero to infinity (AUCinf) of verinurad, allopurinol and oxypurinol.
Evaluation of the relative bioavailability of VAO after dosing with verinurad/allopurinol FDC capsule and free combinations of V/A under fasted conditions by AUClast [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast) of verinurad, allopurinol and oxypurinol.
Evaluation of the relative bioavailability of VAO after dosing with verinurad/allopurinol FDC capsule and free combinations of V/A under fasted conditions by Cmax [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Maximum observed plasma (peak) drug concentration (Cmax) of verinurad, allopurinol and oxypurinol.

Secondary Outcome Measures

Evaluation of the relative bioavailability of VAO after dosing with with the verinurad/allopurinol FDC capsule and with free combinations of V/A under fed and fasted conditions by AUCinf [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Area under plasma concentration time curve from time zero to infinity of verinurad, allopurinol and oxypurinol.
Evaluation of the relative bioavailability of VAO after dosing with with the verinurad/allopurinol FDC capsule and with free combinations of V/A under fed and fasted conditions by AUClast [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Area under the plasma concentration time curve from time zero to time of last quantifiable concentration of verinurad, allopurinol and oxypurinol.
Evaluation of the relative bioavailability of VAO after dosing with with the verinurad/allopurinol FDC capsule and with free combinations of V/A under fed and fasted conditions by Cmax [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Maximum observed plasma (peak) drug concentration of verinurad, allopurinol and oxypurinol.
Evaluation of the relative bioavailability of verinurad after dosing with the verinurad gelatin capsule and verinurad/allopurinol FDC capsule under fasted conditions by AUCinf [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Area under plasma concentration time curve from time zero to infinity of verinurad, allopurinol and oxypurinol.
Evaluation of the relative bioavailability of verinurad after dosing with the verinurad gelatin capsule and verinurad/allopurinol FDC capsule under fasted conditions by AUClast [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Area under the plasma concentration time curve from time zero to time of last quantifiable concentration of verinurad, allopurinol and oxypurinol.
Evaluation of the relative bioavailability of verinurad after dosing with the verinurad gelatin capsule and verinurad/allopurinol FDC capsule under fasted conditions by Cmax [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Maximum observed plasma (peak) drug concentration of verinurad, allopurinol and oxypurinol.
Assessment of the pharmacokinetic (PK) profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by AUCinf [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Area under plasma concentration time curve from time zero to infinity of verinurad, allopurinol and oxypurinol.
Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by AUClast [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Area under the plasma concentration time curve from time zero to time of last quantifiable concentration of verinurad, allopurinol and oxypurinol.
Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by Cmax [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Maximum observed plasma (peak) drug concentration of verinurad, allopurinol and oxypurinol.
Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by tmax [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Time to reach maximum observed plasma concentration following drug administration (tmax) of verinurad, allopurinol and oxypurinol.
Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by tlag [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Time delay between drug administration and the first observed concentration in plasma (tlag) of verinurad, allopurinol and oxypurinol.
Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by λz [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Terminal elimination rate constant (λz) of verinurad, allopurinol and oxypurinol.
Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by t½λz [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t½λz) of verinurad, allopurinol and oxypurinol.
Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by CL/F [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Apparent total body clearance of drug from plasms after extravascular administration (parent drug only) (CL/F) of verinurad, allopurinol and oxypurinol.
Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by MRTinf [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRTinf) of verinurad, allopurinol and oxypurinol.
Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by Vss/F [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Volume of distribution (apparent) at steady state following extravascular administration (Vss/F) of verinurad, allopurinol and oxypurinol.
Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by Vz/F [Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose)]
Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of verinurad, allopurinol and oxypurinol.
Number of subjects with serious and non-serious adverse events [From Screening (Days -28 to -2) to follow-up visit (7 to 14 days post final dose)]
Assessment of the safety of single doses of verinurad and allopurinol.
Assessment of the pharmacodynamics (PD) of VAO when administered as verinurad/allopurinol FDC capsule and free combinations of V/A under fed and fasted conditions and of verinurad gelatin capsule under fasted conditions by observed values and percentage [Day -1 (-24, -23, -22, -21, -20, -19, -18, -16, -14 and -12 h), Day 1 to 4 (Day 1: Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose Day 2: 24 h, Day 3: 48 h post-dose, Day 4: 72 h post-dose)]
Observed values and percentage change from baseline [CB] (time matched, Day -1) in serum uric acid [sUA] concentrations at each time point following administration of verinurad and allopurinol (verinurad only for Treatment 5) in each treatment period
Assessment of the PD of VAO when administered as verinurad/allopurinol FDC capsule and free combinations of V/A under fed and fasted conditions and of verinurad gelatin capsule under fasted conditions by Emax, CB [Day -1 (-24, -23, -22, -21, -20, -19, -18, -16, -14 and -12 h), Day 1 to 4 (Day 1: Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose Day 2: 24 h, Day 3: 48 h post-dose, Day 4: 72 h post-dose)]
Maximum percentage CB (time matched, Day -1) in sUA concentrations.
Assessment of the PD of VAO when administered as verinurad/allopurinol FDC capsule and free combinations of V/A under fed and fasted conditions and of verinurad gelatin capsule under fasted conditions by tEmax, CB [Day -1 (-24, -23, -22, -21, -20, -19, -18, -16, -14 and -12 h), Day 1 to 4 (Day 1: Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose Day 2: 24 h, Day 3: 48 h post-dose, Day 4: 72 h post-dose)]
Time of maximum percentage CB (time-matched, Day -1) in sUA concentration.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 50 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Provision of signed and dated, written informed consent prior to any study specific procedures.
Healthy male and female subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture.
Have a body mass index between 18 and 30 kg/m^2 (inclusive) and weigh at least 50 kg and no more than 100 kg (inclusive).
Females must have a negative pregnancy test at screening and on admission to the unit and must be:

not pregnant or currently lactating or breastfeeding.
of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria: (i) postmenopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) levels in the postmenopausal range (FSH levels

40 IU/mL).

(ii) documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

OR if of childbearing potential must be willing to use an acceptable method of contraception to avoid pregnancy for the entire study period.

Must be able to swallow multiple capsules and tablets.

Exclusion Criteria:

History of gout or any clinically significant disease which, in the opinion of the principal investigator (PI), may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of verinurad.
History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results as judged by the Investigator at screening and first admission, including:

Alanine aminotransferase > 1.5 x upper limit of normal (ULN),
Aspartate aminotransferase > 1.5 x ULN,
Bilirubin (total) > 1.5 x ULN,
Gamma glutamyl transpeptidase > 1.5 x ULN.

Any clinically significant abnormal findings in vital signs at the Screening Visit and/or admission to the Clinical Unit, including, but not limited to, any of the following:

Pulse (resting, supine) < 50 beats per minute (bpm) or > 90 bpm,
Systolic blood pressure (BP) < 90 mmHg or > 140 mmHg and/or diastolic BP < 50 mmHg or > 90 mmHg sustained for > 10 minutes while resting in a supine position.

Any clinically significant abnormalities on 12 lead electrocardiogram (ECG) at the

Screening Visit, including, but not limited to any of the following:

QTcF > 450 ms or < 340 ms or family history of long QT syndrome,
Any significant arrhythmia
Conduction abnormalities
Clinically significant PR (PQ) interval prolongation (> 240 ms); intermittent second or third degree AV block, or AV dissociation
Complete bundle branch block and/or QRS duration > 120 ms.

Any positive result at the Screening Visit for serum Hepatitis B surface antigen or Anti Hepatitis B core antibody, hepatitis virus C antibody, and human immunodeficiency virus antibody.
Suspicion or known Gilbert's and/or Lesch Nyhan syndrome.
Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the PI.
Has received another new chemical or biological entity within 30 days or at least 5 half lives of the first administration of verinurad in this study.
Subjects who have previously received verinurad.
Plasma donation within 1 month of screening or any blood donation/loss of more than 500 mL during the 3 months prior to the Screening Visit.
Subjects who are pregnant, lactating or planning to become pregnant.
Hypersensitivity to verinurad, allopurinol or any drug with a similar chemical structure/class to verinurad and/or allopurinol.
Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the 3 months prior to screening.
Excessive intake of caffeine containing drinks or food as judged by the PI.
Positive screen for drugs of abuse or cotinine (nicotine) at the Screening Visit or positive screen for alcohol, drugs of abuse and cotinine on each admission to the study centre.
Use of drugs with enzyme inducing properties within 3 weeks prior to the first administration of verinurad.
Use of any prescribed or non prescribed medication including antacids, analgesics, herbal remedies, megadose vitamins and minerals during the 2 weeks prior to the first administration of verinurad or longer if the medication has a long half life.
Any AstraZeneca, Parexel or study site employee or their close relatives.
Subjects who cannot communicate reliably with the PI and/or is not able to read, speak and understand the German language.
Judgment by the PI that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Subjects with any special dietary restrictions such as subjects that are lactose intolerant or are vegetarians/vegans.
Subject is a carrier of the HLA B*58:01 allele.
Subject has a positive test result for severe acute respiratory syndrome corona virus (SARS-CoV-2) RT-PCR before randomisation.
Subject has clinical signs and symptoms consistent with Coronavirus disease 2019 (COVID-19), eg, fever, dry cough, dyspnoea, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission.
History of severe COVID-19 (hospitalisation, extracorporeal membrane oxygenation, mechanically ventilated).
Subjects who are regularly exposed to COVID-19 as part of their daily life.
Subjects who have had or are planning to have the COVID-19 vaccination within 4 weeks prior to screening or at any time during the study.